Massachusetts-based biotechnology firm Selecta Biosciences announced it commenced a Phase I trial of its lead product, SEL-068, a nicotine vaccine for smoking cessation. Unlike the traditional flu vaccine, which is...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)